Non-myeloablative conditioning and allogeneic transplantation for multiple myeloma

American Journal of Hematology

Volumn 85, Issue 4, 2010, Pages 249-254

  Osman, Keren ^a   Elliott, Brian ^a   Mandeli, John ^a   Scigliano, Eileen ^a   Malone, Adriana ^a   Isola, Luis ^a   Grosskreutz, Celia ^a  

^a MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 MICROGLOBULIN; BORTEZOMIB; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DEXAMETHASONE; DOXORUBICIN; FLUDARABINE; MELPHALAN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; THALIDOMIDE; THIOTEPA; THYMOCYTE ANTIBODY; VINCRISTINE;

ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; AGE DISTRIBUTION; AGED; ALLOTRANSPLANTATION; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM INFECTION; CLINICAL ARTICLE; DRUG DOSE REDUCTION; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LEUKEMIA REMISSION; MALE; MORTALITY; MULTIPLE MYELOMA; NONMYELOABLATIVE CONDITIONING; OVERALL SURVIVAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SEPSIS; WHOLE BODY RADIATION;

ADULT; AGED; AGING; ANTILYMPHOCYTE SERUM; BETA 2-MICROGLOBULIN; COHORT STUDIES; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; MULTIPLE MYELOMA; MYELOABLATIVE AGONISTS; RECURRENCE; RETROSPECTIVE STUDIES; SALVAGE THERAPY; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; VIDARABINE; WHOLE-BODY IRRADIATION;

EID: 77950419943     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21633     Document Type: Article

References (35)

1. SEER (Surveillance, Epidemiology and End Results) Cancer Statistics Review (1975-2002). Bethesda, MD: National Cancer Institute; 2005.
2. Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999;341:1565-1571.
3. Attal M, Moreau P, Avet-Loiseau H, Harousseau J-L. Stem cell transplantation in multiple myeloma. Hematol Am Soc Hematol Educ Program 2007;2007:311-316.
4. Bjorkstrand BB, Ljungman P, Svensson H, et al. Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: A retrospective case-matched study from the European group for blood and marrow transplantation. Blood 1996;88:4711-4718. (Pubitemid 26419156)
5. Tricot G, Vesole DH, Jagannath S, et al. Graft-versus-myeloma effect: Proof of principle. Blood 1996;87:1196-1198.
6. Mehta J, Singhal S. Graft-versus-myeloma. Bone Marrow Transplant 1998;22:835-843.
7. Champlin R, Khouri I, Kornblau S, et al. Allogeneic hematopoietic transplantation as adoptive immunotherapy. Induction of graft-versus-malignancy as primary therapy. Hematol Oncol Clin North Am 1999;13:1041-1057,vii-viii.
8. Hunter HM, Peggs K, Powles R, et al. Analysis of outcome following allogeneic haemopoietic stem cell transplantation for myeloma using myeloablative conditioning-Evidence for a superior outcome using melphalan combined with total body irradiation. Br J Haematol 2005;128:496-502. (Pubitemid 40283167)
9. Barlogie B, Shaughnessy J, Tricot G, et al. Treatment of multiple myeloma. Blood 2004;103:20-32.
10. Kroger N. Autologous-allogeneic tandem stem cell transplantation in patients with multiple myeloma. Leuk Lymphoma 2005;46:813-821. (Pubitemid 40959670)
11. Bruno B, Rotta M, Patriarca F, et al. A comparison of allografting with autografting for newly diagnosed myeloma. N Engl J Med 2007;356:1110-1120. (Pubitemid 46425595)
12. Garban F, Attal M, Michallet M, et al, for the intergroupe Francophone du myelome and the Swiss group for clinical cancer R. Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma. Blood 2006;107:3474-3480.
13. Kroger N, Schwerdtfeger R, Kiehl M, et al. Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma. Blood 2002;100:755-760.
14. Maloney DG, Molina AJ, Sahebi F, et al. Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood 2003;102:3447-3454. (Pubitemid 37314788)
15. Galimberti S, Benedetti E, Morabito F, et al. Prognostic role of minimal residual disease in multiple myeloma patients after non-myeloablative allogeneic transplantation. Leuk Res 2005;29:961-966. (Pubitemid 40840724)
16. Georges GE, Maris MB, Maloney DG, et al. Nonmyeloablative unrelated donor hematopoietic cell transplantation to treat patients with poor-risk, relapsed, or refractory multiple myeloma. Biol Blood Marrow Transplant 2007;13:423-432. (Pubitemid 46421886)
17. Crawley C, Iacobelli S, Bjorkstrand B, et al, for the chronic leukaemia working party of the European group for blood and marrow T. Reduced-intensity conditioning for myeloma: Lower nonrelapse mortality but higher relapse rates compared with myeloablative conditioning. Blood 2007;109:3588-3594.
18. Kroger N, Schilling G, Einsele H, et al. Deletion of chromosome band 13q14 as detected by fluorescence in situ hybridization is a prognostic factor in patients with multiple myeloma who are receiving allogeneic dose-reduced stem cell transplantation. Blood 2004;103:4056-4061. (Pubitemid 38685344)
19. Einsele H, Schäfer HJ, Hebart H, et al. Follow-up of patients with progressive multiple myeloma undergoing allografts after reduced-intensity conditioning. Br J Haematol 2003;121:411-418. (Pubitemid 36628332)
20. Majolino I, Davoli M, Carnevalli E, et al, Gitmo institutions. Reduced intensity conditioning with thiotepa, fludarabine, and melphalan is effective in advanced multiple myeloma. Leuk Lymphoma 2007;48:759-766.
21. de Lavallade H, El-Cheikh J, Faucher C, et al. Reduced-intensity conditioning allogeneic SCT as salvage treatment for relapsed multiple myeloma. Bone Marrow Transplant 2008;41:953-960.
22. Crawley C, Lalancette M, Szydlo R, et al, for the chronic leukaemia working party of the EBMT. Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: An analysis of prognostic factors from the chronic leukaemia working party of the EBMT. Blood 2005;105:4532-4539.
23. Badros A, Barlogie B, Morris C, et al. High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions. Blood 2001;97:2574-2579.
24. Kroger N, Sayer HG, Schwerdtfeger R, et al. Unrelated stem cell transplantation in multiple myeloma after a reduced-intensity conditioning with pretransplantation antithymocyte globulin is highly effective with low transplantation-related mortality. Blood 2002;100:3919-3924. (Pubitemid 35402053)
25. Gerull S, Goerner M, Benner A, et al. Long-term outcome of nonmyeloablative allogeneic transplantation in patients with high-risk multiple myeloma. Bone Marrow Transplant 2005;36:963-969. (Pubitemid 41741559)
26. Shimazaki C, Fujii H, Yoshida T, et al. Reduced-intensity conditioning allogeneic stem cell transplantation for multiple myeloma: Results from the Japan myeloma study group. Int J Hematol 2005;81:342-348. (Pubitemid 41702098)
27. Lee CK, Zangari M, Fassas A, et al. Clonal cytogenetic changes and myeloma relapse after reduced intensity conditioning allogeneic transplantation. Bone Marrow Transplant 2006;37:511-515.
28. Perez-Simon JA, Sureda A, Fernandez-Aviles F, et al. Reduced-intensity conditioning allogeneic transplantation is associated with a high incidence of extramedullary relapses in multiple myeloma patients. Leukemia 2006;20:542-545. (Pubitemid 43291766)
29. Grosskreutz C, Ross V, Scigliano E, et al. Low-dose total body irradiation, fludarabine, and antithymocyte globulin conditioning for nonmyeloablative allogeneic transplantation. Biol Blood Marrow Transplant 2003;9:453-459. (Pubitemid 38351803)
30. Grosskreutz C, Scigliano E, Osman K, Isola L. Graft versus host disease after stem cell allotransplantation with low-dose total body irradiation, fludarabine, and antithymocyte globulin. Transplantation 2007;84:598-604. (Pubitemid 47429040)
31. Greipp PR, San Miguel J, Durie BG, et al. International staging system for multiple myeloma. J Clin Oncol 2005;23:3412-3420.
32. van Dorp S, Meijer E, van de Donk N, et al. Single-centre experience with nonmyeloablative allogeneic stem cell transplantation in patients with multiple myeloma: Prolonged remissions induced. Neth J Med 2007;65:178-184. (Pubitemid 47177040)
33. Ash RC, Horowitz MM, Gale RP, et al. Bone marrow transplantation from related donors other than HLA-identical siblings: Effect of T cell depletion. Bone Marrow Transplant 1991;7:443-452.
34. Kroger N, Zabelina T, Kruger W, et al. In vivo T cell depletion with pretransplant anti-thymocyte globulin reduces graft-versus-host disease without increasing relapse in good risk myeloid leukemia patients after stem cell transplantation from matched related donors. Bone Marrow Transplant 2002;29:683-689.
35. Doney KC, Weiden PL, Storb R, Thomas ED. Failure of early administration of antithymocyte globulin to lessen graft-versus-host disease in human allogeneic marrow transplant recipients. Transplantation 1981;31:141-143.